Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$9.13
-0.3%
$9.11
$0.06
$14.93
$6.97M0.98558,246 shs2,754 shs
LadRx Corp stock logo
CYTR
LadRx
$0.09
$0.05
$0.86
$4.14MN/A99,706 shs4,000 shs
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$0.11
+9.9%
$0.09
$0.06
$0.24
$8.16M0.3665,394 shs61,501 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
$14.75
$110K1.37120,908 shs23,886 shs
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
$4.13
+1.5%
$16.75
$0.70
$3.46
$45.48M1.04648,892 shs715,760 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-0.04%+3.62%+0.33%+0.33%-75.22%
LadRx Corp stock logo
CYTR
LadRx
0.00%0.00%0.00%0.00%0.00%
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
+3.95%-3.85%+21.95%+5.71%-41.18%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%-95.12%
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.00%+11.20%+6.82%+45.88%+62.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
1.1352 of 5 stars
3.50.00.00.01.10.00.0
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/AN/AN/AN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$275.002,913.70% Upside
LadRx Corp stock logo
CYTR
LadRx
0.00
N/AN/AN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
0.00
N/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00
N/AN/AN/A
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$146K47.75N/AN/A$0.20 per share45.63
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/AN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$30K271.86$0.01 per share9.18$0.04 per share2.75
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$12.05M0.01$1.61 per share0.02($0.37) per share-0.09
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
$250K181.90N/AN/A$0.94 per share4.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/A
LadRx Corp stock logo
CYTR
LadRx
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
$780K-$0.01N/AN/AN/A-22.19%-1.28%8/6/2025 (Estimated)
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
-$3.59M$3.730.01N/AN/A-237.65%57.29%N/A
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
-$16.41M-$2.80N/AN/A-3,688.31%-202.00%-122.92%N/A

Latest TCON, ENZN, CYTR, TROV, and AIM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A-$0.01N/A-$0.01N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.05
0.75
0.75
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A
82.17
82.17
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/A
0.66
0.66
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.12
2.37
2.37

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
LadRx Corp stock logo
CYTR
LadRx
N/A
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
11.61%
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
9.99%
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
20764,00068.74 millionNot Optionable
LadRx Corp stock logo
CYTR
LadRx
N/A45.04 millionN/ANot Optionable
Enzon Pharmaceuticals Inc. stock logo
ENZN
Enzon Pharmaceuticals
N/A74.21 million73.92 millionNot Optionable
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
203.41 million3.23 millionNo Data
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/A11.01 millionN/ANot Optionable

Recent News About These Companies

Cardiff Oncology announces second patent for onvansertib combination
William Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)
Cardiff Oncology Reports Positive Q3 2024 Results and Clinical Progress

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIM ImmunoTech stock logo

AIM ImmunoTech NYSE:AIM

$9.12 -0.03 (-0.27%)
As of 12:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

LadRx stock logo

LadRx NASDAQ:CYTR

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Enzon Pharmaceuticals stock logo

Enzon Pharmaceuticals OTCMKTS:ENZN

$0.11 +0.01 (+9.90%)
As of 11:30 AM Eastern

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

TRACON Pharmaceuticals stock logo

TRACON Pharmaceuticals NASDAQ:TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:TROV

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.